GLP-1 Medications in 2026.

GLP-1 receptor agonists are the most consequential drug class to hit American workplaces since statins. Searches for Ozempic, Wegovy, Zepbound, and tirzepatide grew triple digits across 2025 and 2026. Behind the search volume sits a real clinical question every benefits leader will get asked this year: are we covering this, and at what cost.

TL;DR — GLP-1 in 60 seconds

• GLP-1s are FDA-approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Byetta, Rybelsus) and for chronic weight management (Wegovy, Zepbound, Saxenda).
• U.S. cash list prices ran $1,000 to $1,350 per month in 2026. Tier-1 country sourcing through licensed international pharmacies typically lands the same molecule between $190 and $375 per month.
• Only 44% of employers with 500+ workers cover GLP-1s for weight loss in 2026. Coverage for diabetes indications is near-universal.
• A Section 125 cafeteria plan plus Tier-1 sourcing plus clinical management routinely lands the all-in member cost under $250 per month, and recaptures roughly $91 per enrolled employee per month for the employer.
• There is no FDA-approved over-the-counter GLP-1. OTC supplement claims do not match the pharmacology.

What is a GLP-1 medication?

GLP-1 stands for glucagon-like peptide-1, a hormone the small intestine releases after a meal. Native GLP-1 tells the pancreas to release insulin, signals the brain that you are full, and slows how quickly the stomach empties. The hormone degrades within minutes of release.

GLP-1 receptor agonists are synthetic peptides engineered to bind the same receptor as native GLP-1 but resist enzymatic breakdown. The earliest GLP-1, exenatide, required twice-daily injection. Modern molecules like semaglutide and tirzepatide are dosed once weekly because their half-life sits around five to seven days. The clinical effect is sustained appetite suppression, improved glycemic control, and meaningful weight loss in most patients who tolerate the medication.

Every GLP-1 on the U.S. market in 2026

Ozempic and Wegovy (semaglutide)

Same molecule, different label. Ozempic carries the FDA indication for type 2 diabetes and dose-titrates to a maximum of 2 mg weekly. Wegovy carries the indication for chronic weight management and titrates to 2.4 mg weekly. Average weight loss in the STEP trials was 14.9% of baseline body weight at 68 weeks.

Mounjaro and Zepbound (tirzepatide)

Tirzepatide is technically a dual GIP and GLP-1 receptor agonist, but functionally it is grouped with the GLP-1 class. Mounjaro carries the diabetes indication, Zepbound the weight management indication. Both titrate up to 15 mg weekly. The SURMOUNT-1 trial reported an average 22.5% weight loss at the highest dose at 72 weeks, the largest weight-loss effect of any FDA-approved medication to date.

Trulicity, Victoza, Rybelsus, Saxenda

Trulicity remains a workhorse weekly diabetes injectable. Victoza and Saxenda share the liraglutide molecule with different indications. Rybelsus is the only oral GLP-1 in broad use, dosed daily, with somewhat lower bioavailability than the injectable forms.

What GLP-1 medications cost in 2026

Cash price vs. insured price

International and compounded sourcing

Two compliant pathways exist for accessing GLP-1s below U.S. retail. The first is brand-name dispensing through licensed Tier-1 country pharmacies, where the same Novo Nordisk or Eli Lilly molecule is available at the local retail price. This pathway requires a valid prescription, identity verification, and a regulated dispensing pharmacy.

The second is compounded semaglutide or tirzepatide produced by FDA-registered 503A or 503B compounding pharmacies. The compounding pathway expanded during the 2023-to-2024 FDA shortage designation. With the shortage formally resolved in late 2024 and early 2025, large-scale compounding of these molecules narrowed substantially. Some specialty programs continue to offer compounded versions, but availability is fragmented and the pathway is more legally constrained than it was eighteen months ago.

Is there an over-the-counter GLP-1?

No. Searches for "over the counter GLP-1" rose roughly 190% in 2026, but as of this writing, every FDA-approved GLP-1 receptor agonist is prescription-only. The OTC supplement market includes products that claim to support GLP-1 activity through botanical ingredients, fiber blends, or amino acid precursors. None of these supplements bind the GLP-1 receptor the way semaglutide or tirzepatide does, and none replicates the clinical weight-loss outcomes documented in the STEP and SURMOUNT trials.

Why employers are paying attention

The premium effect

GLP-1 utilization is a measurable contributor to the 2026 health insurance premium increase. Mercer's 2026 employer survey identified specialty drugs, with GLP-1s leading, as one of the top three drivers of the year's medical-trend acceleration. Plans that left GLP-1 coverage open without any clinical-management or formulary architecture saw their specialty-pharmacy line items grow 40% to 70% year over year.

Absenteeism and presenteeism math

The other side of the cost ledger is real. Obesity and type 2 diabetes generate measurable absenteeism, presenteeism, and downstream cardiometabolic claims. Multi-year actuarial studies suggest sustained GLP-1 therapy can reduce cardiometabolic event rates and trim per-member-per-year total medical spend within a three-to-five-year window. Whether that horizon matches the average employee tenure at a specific employer is the strategic question.

How to cover GLP-1 without breaking the budget

The Section 125 path

GLP-1 prescriptions, when prescribed for an FDA-approved indication and dispensed through a recognized pharmacy benefit, are qualified medical expenses under IRC §213(d). That means the employee share of the prescription can be funded with pre-tax dollars routed through a Section 125 cafeteria plan. For the median W-2 employee, pre-tax routing shaves 22% to 32% off the effective price by eliminating federal income tax, FICA, and most state income tax on the dollars used to pay for the prescription. The employer recaptures roughly $91 per enrolled employee per month in FICA on the same election.

Tier-1 country sourcing

Tier-1 sourcing layers on top. The Benecor pharmacy benefit includes brand-name GLP-1 dispensing through licensed Tier-1 country pharmacies at $190 to $375 per month all-in. Combined with §125 pre-tax routing and a clinical-management touchpoint, the typical member out-of-pocket lands under $250 per month for the same brand-name semaglutide or tirzepatide that retails for $1,200 in the U.S.

The 2026 employer GLP-1 playbook

• Decide the indication scope. Cover diabetes indications by default. For weight management, set a clear clinical threshold (BMI 30, or 27 with documented comorbidity) and require a credentialed prescribing pathway.
• Layer the financial structure. Section 125 cafeteria plan first. Tier-1 country sourcing for cost-relevant molecules. Manufacturer savings card where eligibility holds. Real pharmacy formulary discipline last.
• Add clinical management. A virtual pharmacist or care navigator measurably trims discontinuation rates, mid-titration side-effect dropouts, and prescription waste. Member experience matters.
• Communicate the math openly. Employees who see the cost structure use the program responsibly. Hidden cost structures generate adverse selection.
• Re-bid annually. The GLP-1 market is moving fast. Manufacturer rebates, generics on the horizon, and new molecules in late-stage trials will reshape the cost curve inside 24 months.

Five GLP-1 program mistakes to avoid

• Open-ended weight-loss coverage with no BMI or comorbidity gate. The actuarial blowout is predictable.
• Relying solely on manufacturer savings cards. 2026 program changes tightened eligibility in ways most plans did not model.
• Ignoring discontinuation. Roughly two-thirds of starts discontinue inside twelve months. Without continuity-of-care support, every restart resets the drug-trend curve.
• Treating compounded GLP-1s as a long-term strategy. The regulatory pathway narrowed materially in 2025.
• Failing to pre-tax the employee share. The §125 structure is the cheapest cost-reduction lever available to the employer and it is left on the table by most plans.

Your next step

If your team is asking about Ozempic, Wegovy, Mounjaro, or Zepbound this year, the answer is not "we cannot afford it." The answer is "here is the structure that makes it work." A Section 125 cafeteria plan layered with Tier-1 country sourcing and a clinical-management touchpoint routinely lands the all-in member cost under $250 per month while the employer recaptures roughly $91 per enrolled employee per month in FICA. We will model the exact number for your payroll in under 48 hours.